Farallon Capital Management Adds $22M in Protagonist Therapeutics, Inc. ($PTGX)
Key Points
- Farallon Capital Management changed its Protagonist Therapeutics, Inc. ($PTGX) stake by 3.3% last quarter, boosting to 6,348,906 shares worth $696.98 million.
- Wall Street's consensus rating on $PTGX is Strong Buy and an average price target of $118.69.
- $PTGX last traded around $109.78.
Farallon Capital Management increased its position in Protagonist Therapeutics, Inc. ($PTGX) by 3.3% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,348,906 shares of Protagonist Therapeutics, Inc. after buying 204,900 shares during the quarter. Farallon Capital Management's holdings in Protagonist Therapeutics, Inc. were worth $696.98 million as of its most recent filing.
Protagonist Therapeutics, Inc. ($PTGX) Stock
Protagonist Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.